Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $730.00 at Morgan Stanley

Summary by marketbeat.com
Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an "equal weight" rating for the company in a research report on Wednesday.

1 Articles

marketbeat.commarketbeat.com
Center

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $730.00 at Morgan Stanley

Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an "equal weight" rating for the company in a research report on Wednesday.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news on Wednesday, July 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Morgan Stanley icon

Morgan Stanley

New York City icon

New York City

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal